127 related articles for article (PubMed ID: 8757966)
1. Suppression of humoral immunity by monoclonal antibody to CD79b, an invariant component of antigen receptors on B lymphocytes.
Nakamura T; Koyama M; Koike Y; Miyazaki K; Yoneyema A; Higashihara M; Azuma M; Kurokawa K
Int J Hematol; 1996 Jul; 64(1):39-46. PubMed ID: 8757966
[TBL] [Abstract][Full Text] [Related]
2. B-cell inhibition by cross-linking CD79b is superior to B-cell depletion with anti-CD20 antibodies in treating murine collagen-induced arthritis.
Brühl H; Cihak J; Talke Y; Rodriguez Gomez M; Hermann F; Goebel N; Renner K; Plachý J; Stangassinger M; Aschermann S; Nimmerjahn F; Mack M
Eur J Immunol; 2015 Mar; 45(3):705-15. PubMed ID: 25471597
[TBL] [Abstract][Full Text] [Related]
3. Bruton's tyrosine kinase is required for signaling the CD79b-mediated pro-B to pre-B cell transition.
Kouro T; Nagata K; Takaki S; Nisitani S; Hirano M; Wahl MI; Witte ON; Karasuyama H; Takatsu K
Int Immunol; 2001 Apr; 13(4):485-93. PubMed ID: 11282988
[TBL] [Abstract][Full Text] [Related]
4. Identification of unique molecular heterogeneity of human CD79, the signaling component of the human B cell antigen receptor (BCR), and synergistic potentiation of the CD79-targeted therapy of B cell tumors by co-targeting of CD79a and CD79b.
Seon BK; Okazaki M; Duzen J; Matsuno F; Goey AKL; Maguire O
Leuk Res; 2024 Jan; 136():107436. PubMed ID: 38232613
[TBL] [Abstract][Full Text] [Related]
5. CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes.
Carter RH; Fearon DT
Science; 1992 Apr; 256(5053):105-7. PubMed ID: 1373518
[TBL] [Abstract][Full Text] [Related]
6. CD79 alpha/CD79 beta heterodimers are expressed on pro-B cell surfaces without associated mu heavy chain.
Koyama M; Ishihara K; Karasuyama H; Cordell JL; Iwamoto A; Nakamura T
Int Immunol; 1997 Nov; 9(11):1767-72. PubMed ID: 9418137
[TBL] [Abstract][Full Text] [Related]
7. Induction of suppressor cells to T- and B-cell proliferative responses and immunoglobulin production by monoclonal antibodies recognizing the CD3 T-cell differentiation antigen.
Kunicka JE; Platsoucas CD
Cell Immunol; 1988 Oct; 116(1):195-215. PubMed ID: 2901914
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of B29 (CD79b) and mb-1 (CD79a) proteins in acute lymphoblastic leukaemia.
Astsaturov IA; Matutes E; Morilla R; Seon BK; Mason DY; Farahat N; Catovsky D
Leukemia; 1996 May; 10(5):769-73. PubMed ID: 8656670
[TBL] [Abstract][Full Text] [Related]
9. CD79: a review.
Chu PG; Arber DA
Appl Immunohistochem Mol Morphol; 2001 Jun; 9(2):97-106. PubMed ID: 11396639
[TBL] [Abstract][Full Text] [Related]
10. In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates.
Zheng B; Fuji RN; Elkins K; Yu SF; Fuh FK; Chuh J; Tan C; Hongo JA; Raab H; Kozak KR; Williams M; McDorman E; Eaton D; Ebens A; Polson AG
Mol Cancer Ther; 2009 Oct; 8(10):2937-46. PubMed ID: 19808977
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibody NU-B1 reacts with novel antigen on human B cells in mantle and marginal zones distinct from known CD molecules.
Matsuo Y; Sugimoto A; Kuwahara K; Watanabe Y; Sakata A; Sakaguchi N; Sagawa K; Orita K
Tissue Antigens; 1998 Nov; 52(5):422-9. PubMed ID: 9864031
[TBL] [Abstract][Full Text] [Related]
12. Helper effector function of human T cells stimulated by anti-CD3 mAb can be enhanced by co-stimulatory signals and is partially dependent on CD40-CD40 ligand interaction.
Kwekkeboom J; de Rijk D; Kasran A; Barcy S; de Groot C; de Boer M
Eur J Immunol; 1994 Mar; 24(3):508-17. PubMed ID: 7510232
[TBL] [Abstract][Full Text] [Related]
13. Anti-idiotype vaccine against Hodgkin's lymphoma: induction of B- and T-cell immunity across species barriers against CD30 antigen by murine monoclonal internal image antibodies.
Pohl C; Renner C; Schwonzen M; Sieber M; Lorenz P; Pfreundschuh M; Diehl V
Int J Cancer; 1992 Apr; 50(6):958-67. PubMed ID: 1313400
[TBL] [Abstract][Full Text] [Related]
14. Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma.
Polson AG; Yu SF; Elkins K; Zheng B; Clark S; Ingle GS; Slaga DS; Giere L; Du C; Tan C; Hongo JA; Gogineni A; Cole MJ; Vandlen R; Stephan JP; Young J; Chang W; Scales SJ; Ross S; Eaton D; Ebens A
Blood; 2007 Jul; 110(2):616-23. PubMed ID: 17374736
[TBL] [Abstract][Full Text] [Related]
15. Cross-linking of antigen receptor via Ig-beta (B29, CD79b) can induce both positive and negative signals in CD40-activated human B cells.
Van Kooten C; Galibert L; Seon BK; Garrone P; Liu YJ; Banchereau J
Clin Exp Immunol; 1997 Dec; 110(3):509-15. PubMed ID: 9409658
[TBL] [Abstract][Full Text] [Related]
16. CD19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced B cell activation and proliferation.
Pezzutto A; Dörken B; Rabinovitch PS; Ledbetter JA; Moldenhauer G; Clark EA
J Immunol; 1987 May; 138(9):2793-9. PubMed ID: 2437199
[TBL] [Abstract][Full Text] [Related]
17. Soluble, but not immobilized, anti-IgM antibody inhibits post-activation events leading to T-cell-dependent B-cell differentiation.
Zamorano J; Rivas D; Gayo A; Mozo L; Gutiérrez C
Immunology; 1995 Jun; 85(2):241-7. PubMed ID: 7642212
[TBL] [Abstract][Full Text] [Related]
18. In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. II. Prolonged suppression of the humoral immune response by an antibody to the ligand for CD40, gp39.
Foy TM; Shepherd DM; Durie FH; Aruffo A; Ledbetter JA; Noelle RJ
J Exp Med; 1993 Nov; 178(5):1567-75. PubMed ID: 7693850
[TBL] [Abstract][Full Text] [Related]
19. Long-term humoral unresponsiveness in vivo, induced by treatment with monoclonal antibody against L3T4.
Goronzy J; Weyand CM; Fathman CG
J Exp Med; 1986 Sep; 164(3):911-25. PubMed ID: 3091757
[TBL] [Abstract][Full Text] [Related]
20. Antigen-specific B-lymphocyte activation.
Bishop GA; Haxhinasto SA; Stunz LL; Hostager BS
Crit Rev Immunol; 2003; 23(3):149-97. PubMed ID: 14584878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
